Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04824092 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Study acronym: frontMIND
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv11
  2. Primary completion date: Jun 2025 to Sep 1, 2026 Completion date: May 2026 to Nov 1, 2027v10 Show 1 more changeShow less
    • Completion date: May 2026 to Nov 1, 2027
  3. Lead sponsor: MorphoSys AG to Incyte Corporationv9
  4. Study sites: 324 to 307v8
  5. Study sites: 437 to 324v7
Show 5 earlier versionsHide 5 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 880 to confirmed 899 · Study sites: 450 to 437v6 Show 2 more changesShow less
    • Enrollment target: estimated 880 to confirmed 899
    • Study sites: 450 to 437
  2. Study sites: 409 to 450 Secondary endpoints: 9 to 10 · Eligibility criteria shortened, about 2 wordsv5 Show 2 more changesShow less
    • Secondary endpoints: 9 to 10
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 360 to 409v4
  4. Study sites: 316 to 360v3
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2021 to May 11, 2021 · Site details revised at 316 of 316 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 2021 to May 11, 2021
    • Site details revised at 316 of 316 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Trial Details
NCT Number NCT04824092
Lead Sponsor Incyte Corporation
Conditions Diffuse Large B-cell Lymphoma
Enrollment 899 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov